Keywords: Basilea, Ceftobiprole, Johnson & Johnson, Cilag, MRSA, CHMP, Licensing
Basilea shares leap as J&J returns rights to MRSA agent after CHMP negative opinion that fuels takeover speculation
Article | 22 February 2010
Switzerland’s Basilea Pharmaceutica saw its share price jump 9% to 73 Swiss francs on February 19, after a negative European regulatory opinion ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
